Khedija Meddeb

Dr. Khedija Meddeb

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2018 in International Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
MDManel Dridi
Manel Dridi
NCNesrine Chraiet
Nesrine Chraiet
RBRim Batti
Rim Batti
MAMouna Ayadi
Mouna Ayadi
AMAmina Mokrani
Amina Mokrani
AMAmel Mezlini
Amel Mezlini
Background. Adult granulosa cell tumors (AGCTs) are the most common sex cord-stromal tumors. Unlike epithelial ovarian tumors, they occur in young women and are usually detected at an early stage. The aim of this study was to report the clinical and pathological characteristics of AGCT patients and to identify the prognostic factors. Methods. All cases of AGCTs, treated at Salah Azaïz Institute between 1995 and 2010, were retrospectively included. Kaplan-Meier’s statistical method was used to assess the relapse-free survival and the overall survival. Results. The final cohort included 31 patients with AGCT. The mean age was 53 years (35–73 years). Patients mainly presented with abdominal mass and/or pain (61%, n=19). Mean tumor size was 20 cm. The majority of patients had a stage I disease (61%, n=19). Two among 3 patients with stage IV disease had liver metastasis. Mitotic index was low in 45% of cases (n=14). Surgical treatment was optimal in almost all cases (90%, n=28). The median follow-up time was 14 years (1–184 months). Ten patients relapsed (32%) with a median RFS of 8.4 years (6.8–9.9 years). Mean overall survival was 13 years (11–15 years). Stage I disease and low-to-intermediate mitotic index were associated with a better prognosis in univariate analysis (resp., p=0.05 and p=0.02) but were not independent prognostic factors. Conclusion. GCTs have a long natural history with common late relapses. Hence, long active follow-up is recommended. In Tunisian patients, hepatic metastases were more frequent than occidental series. The prognosis remains good and initial staging at diagnosis is an important prognostic factor.

9 March 2017 in Clinical Sarcoma Research
Verified
Journal Article
Open access
PDF file
KBK. Behi
K. Behi
MAM. Ayadi
M. Ayadi
EMEssia mezni
Essia mezni
KMKhedija Meddeb
Khedija Meddeb
AMA. Mokrani
A. Mokrani
AMA. Mezlini
A. Mezlini
Cardiac tumors are a very rare entity. Leiomyosarcoma represents less than 1% of cases. a 51-year-old woman diagnosed with primary left atrium leiomyosarcoma. She was treated by optimal surgery and adjuvant chemotherapy. She is still alive after a follow-up of 24 months without evidence of local or distant recurrence. Cardiac leiomyosarcoma is a rare tumor with a dismal prognosis. Surgery is the mainstay of treatment. Adjuvant treatment is still controversial.

20 October 2016 in Translational Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
FMFahmi Mghirbi
Fahmi Mghirbi
MAMouna Ayadi
Mouna Ayadi
WKWafa Karray
Wafa Karray
YYYosra Yahyaoui
Yosra Yahyaoui
KMKhedija Meddeb
Khedija Meddeb
AMAmel Mezlini
Amel Mezlini
Gallbladder cancer is the most common malignant tumor of the biliary tract. The majority of cases are adenocarcinoma (AC). Pure squamous cell carcinoma (SCC) of gallbladder accounts only 3% of the malignant neoplasm of this organ. Many patients are at advanced stage when diagnosed and have bad therapeutic efficacy. At present, radical surgery is the only chance to gain long-term survival for patients with early-stage gallbladder cancers. Recent reports have shown a benefit of adjuvant chemoradiation in this type of tumor. At present, no therapy is defined for unresectable cancer of the gallbladder, especially for SCC.

1 January 2017 in Cancer Biology & Medicine
Verified
Journal Article
Open access
PDF file
FLFeryel Letaief
Feryel Letaief
MNMeher Nasri
Meher Nasri
MAMouna Ayadi
Mouna Ayadi
KMKhedija Meddeb
Khedija Meddeb
AMAmina Mokrani
Amina Mokrani
AMAmel Mezlini
Amel Mezlini
Objective: To assess the response rate of patients with rectal adenocarcinoma to neoadjuvant therapy and to identify the predictorsof histological regression after neoadjuvant radiotherapy (RT) or concurrent chemoradiotherapy (CCRT). Methods: This study recruited 64 patients. The patients had resectable cancer of the lower and the middle rectum (T3/T4 and/orN+) without distant metastasis and received neoadjuvant RT or CCRT followed by radical surgery with total mesorectal excision(TME) between January 2006 and December 2011. The patients were classified into non-response (NR), partial response (PR), andpathologic complete response (pCR) based on the Dworak tumor regression grading system. Results: The median age of patients was 57 years (ranging from 22 to 85). A total of 24 patients were treated with neoadjuvantCCRT, whereas 40 patients were treated with RT alone. Abdominoperineal resection (APR) was performed on 29 patients (45%).Anterior resection with TME was performed on 34 patients (53%). One patient had local resection. Histologically, 12 (19%), 24(73%), and 28 (44%) patients exhibited pCR, PR, and NR, respectively. Univariate analysis revealed that the predictors of tumorregression were as follows: the absence of lymph node involvement from initial imaging (cN0) (P=0.021); normal initialcarcinoembryonic antigen (CEA) level (P=0.01); hemoglobin level ≥12 g/dl (P=0.009); CCRT (P=0.021); and tumor downstagingin imaging (P=0.001). Multivariate analysis showed that the main predictors of pCR were CT combined with neoadjuvant RT, cN0stage, and tumor regression on imaging. Conclusions: Identifying the predictors of pCR following neoadjuvant therapy aids the selection of responsive patients for nonaggressivesurgical treatment and possible surveillance.

5 December 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
HKHyem Khiari
Hyem Khiari
KMKarima Makni
Karima Makni
KMKhedija Meddeb
Khedija Meddeb
OJOlfa Jaidane
Olfa Jaidane
MHMohamed Hsairi
Mohamed Hsairi
Objectives The objective of this study is to assess the cost utility of the implementation of the human papillomavirus (HPV) vaccination programme in Tunisia in addition to the current cytology screening strategy. This study is very important to guide health policy decision-makers and to help them allocate their scarce healthcare resources. Design We used a previously described Markov model on the Online Cost Effectiveness Analysis tool programmed with R Software. The Markov cohort model was used to simulate the natural history of HPV infection and cervical cancer for a cohort of 100 000 females aged from 10 to 84 years. The model was calibrated with Tunisian parameters to calculate the long-term health benefits and costs of different cervical cancer preventive strategies in Tunisia. Outcome measures The primary outcome was the incremental cost-effectiveness ratio (ICER) of the implementation of HPV vaccination to the current cytology screening strategy to fight against cervical cancer. The ICER was calculated per life-years saved and per quality-adjusted life-year (QALY) gained, expressed in 2020 US$. Thresholds were fixed at one to three times the gross domestic product (GDP). One-way sensitivity analyses were carried out concerning the coverage rate of the cytology screening and vaccination as well as for the vaccination cost and doses. Results Compared with screening alone, the combined strategy predicted an ICER of US$1920.8 year of life saved and US$2239.3/QALY which is still lower than the GDP per capita of Tunisia in 2020 (US$3319). Sensitivity analysis showed that the cost-effectiveness of adding vaccination to the existing screening programme did not exceed the GDP per capita by varying the cost per dose upwards to US$45 (ICER would be US$2910/QALY) and vaccination coverage up to 100% (ICER of US$3245/QALY). However, the combined strategy exceeds the GDP per capita threshold when the cytological screening coverage rises to 70%, causing the ICER to rise to US$4787/QALY. Conclusion This study showed that compared with screening alone, the implementation of HPV vaccination in addition to the current cytology screening programme in Tunisia would be considered cost-effective on the basis of the threshold GDP per capita. Improvement of the current screening programme itself also remains important and provides further potential to achieve optimal cervical cancer prevention strategies.

1 November 2018 in Urology Case Reports
Verified
Journal Article
Open access
AMAmina Mokrani
Amina Mokrani
FGFatma Guermazi
Fatma Guermazi
KMKhedija Meddeb
Khedija Meddeb
LKLinda Bel Hadj Kacem
Linda Bel Hadj Kacem
MCMarouene Chakroun
Marouene Chakroun
AMAmel Mezlini
Amel Mezlini